Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

How MSI and TMB Factor into Current Biomarker Testing Panels

Videos - Video, ASCO
Sanjiv Agarwala, MD
Dr Sanjiv Agarwala discusses the usefulness of MSI and TMB as novel biomarkers for various cancer types. His argument is that the first FDA approval of a therapy based on MSI rather than tumor type makes this biomarker useful, but TMB is not yet ready for “prime time.”
Related Items
FDA Unveils Pilot Program to Expand Access to Investigational Oncology Drugs
Phoebe Starr
Web Exclusives published on July 29, 2019 in ASCO
Working Together to Find the New Standard of Care
Andrey Antov, PhD, MBA
Videos published on September 6, 2018 in Video
Opportunities Are Abundant for Navigators in the Field of Genetics and Genomics
Andrey Antov, PhD, MBA
Videos published on September 6, 2018 in Video
Healthcare Team's Relationship to the Patient
Andrey Antov, PhD, MBA
Videos published on September 6, 2018 in Video
The Navigator's Role in Genetic Testing
Andrey Antov, PhD, MBA
Videos published on September 6, 2018 in Video
Why Are Clinical Trials Important?
Andrey Antov, PhD, MBA
Videos published on September 6, 2018 in Video
Educating Oncology Professionals on Genetic and Genomic Testing
Andrey Antov, PhD, MBA
Videos published on September 6, 2018 in Video
Who Should Consider Genetic Testing?
Andrey Antov, PhD, MBA
Videos published on September 6, 2018 in Video
What the Next Generation of Cancer Biomarkers May Involve
Sanjiv Agarwala, MD
Videos published on July 25, 2018 in Video, ASCO
Best Practices in How Oncologists and Pathologists Can Work Together to Optimize Biomarker Testing for their Patients with Cancer
Sanjiv Agarwala, MD
Videos published on July 25, 2018 in Video, ASCO
Last modified: July 25, 2018